Acolbifene (EM-652) hydrochloride 是 EM800 的活性代谢产物,是一种口服活性的选择性雌激素受体调节剂(SERM)。Acolbifene (EM-652) hydrochloride 抑制雌二醇诱导的 ERα (IC50= 2 nM) 和 ERβ (IC50= 0.4 nM) 转录活性。Acolbifene (EM-652) hydrochloride 对乳腺和子宫有明显的抗雌激素作用。Acolbifene (EM-652) hydrochloride 具有抗癌活性。
生物活性 | Acolbifene (EM-652) hydrochloride, an active metabolite of EM800, is an orally active, cancer-preventingselectiveestrogen receptor modulator(SERM). Acolbifene (EM-652) hydrochloride inhibits estradiol (E2)-induced transcriptional activity ofERα(IC50=2 nM) andERβ(IC50=0.4 nM). Acolbifene (EM-652) hydrochloride exerts a potent and pure antiestrogenic action in the mammary gland and uterus. Anticarcinogenic properties[1][2][3][4][5]. |
IC50& Target[5] | ERα 2 nM (IC50, E2-induced transcriptional activity) | ERβ 0.4 nM (IC50, E2-induced transcriptional activity) |
|
体外研究 (In Vitro) | Acolbifene (ACOL) does not affect pathways of cholesterol synthesis, supporting the involvement of the clearance-related receptors in its hypocholesterolemic action[2]. Acolbifene (EM-652) shows no agonistic activity on ERα and ERβ transcriptional function and blocks the estradiol (E2)-mediated activation of both ERα and ERβ[3]. Acolbifene (EM-652) shows the most potent inhibition of estradiol-stimulated cell proliferation in human breast cancer cells (ZR-75-1, MCF-7, T-47D) and is devoid of any intrinsic estrogenic activity[4].
|
体内研究 (In Vivo) | Acolbifene (ACOL) reduces food intake and strongly decreases cholesterolemia in rats fed a cholesterol-free diet[2]. Acolbifene (ACOL) reduces food intake (16%) and weight gain (45%, mainly fat) similarly in both dietary cohorts[2].
Animal Model: | Female Sprague-Dawley rats (n = 42) initially weighing 175-200 g[2]. | Dosage: | 2.5 mg/kg. | Administration: | Oral gavage, once daily for 21 d. | Result: | Prevents tumor growth in rats. |
|
Clinical Trial | |
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
溶解性数据 | In Vitro: DMSO : 180 mg/mL(364.36 mM;Need ultrasonic) 配制储备液 1 mM | 2.0242 mL | 10.1210 mL | 20.2421 mL | 5 mM | 0.4048 mL | 2.0242 mL | 4.0484 mL | 10 mM | 0.2024 mL | 1.0121 mL | 2.0242 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 4.5 mg/mL (9.11 mM); Clear solution
此方案可获得 ≥ 4.5 mg/mL (9.11 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 45.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 4.5 mg/mL (9.11 mM); Clear solution
此方案可获得 ≥ 4.5 mg/mL (9.11 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 45.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 4.5 mg/mL (9.11 mM); Clear solution
此方案可获得 ≥ 4.5 mg/mL (9.11 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 45.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|